Farallon Capital Management LLC Invests $113,000 in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Farallon Capital Management LLC acquired a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 13,000 shares of the biotechnology company’s stock, valued at approximately $113,000.

Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Ironwood Pharmaceuticals by 61.4% during the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after buying an additional 822 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Ironwood Pharmaceuticals by 331.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,900 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,645 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Ironwood Pharmaceuticals by 68.8% in the 4th quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 3,497 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $91,000.

Analysts Set New Price Targets

Several brokerages recently weighed in on IRWD. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Craig Hallum dropped their price target on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $18.40.

Ironwood Pharmaceuticals Trading Down 0.9 %

NASDAQ:IRWD traded down $0.06 on Friday, hitting $6.53. The stock had a trading volume of 1,615,155 shares, compared to its average volume of 1,589,025. Ironwood Pharmaceuticals, Inc. has a 1 year low of $5.47 and a 1 year high of $15.70. The firm’s fifty day simple moving average is $6.39 and its two-hundred day simple moving average is $8.85.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). The company had revenue of $74.90 million during the quarter, compared to the consensus estimate of $105.75 million. Ironwood Pharmaceuticals had a negative return on equity of 28.45% and a negative net margin of 254.41%. The company’s revenue for the quarter was down 28.0% compared to the same quarter last year. During the same period last year, the firm posted $0.25 EPS. On average, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the sale, the director now owns 84,207 shares of the company’s stock, valued at approximately $535,556.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares in the company, valued at approximately $535,556.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie Mchugh sold 22,766 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $6.29, for a total transaction of $143,198.14. Following the transaction, the director now owns 139,528 shares of the company’s stock, valued at $877,631.12. The disclosure for this sale can be found here. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.